Woodline Partners’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.9M Buy
+551,837
New +$3.43M 0.01% 821
2020
Q4
– Sell
-43,256
Closed -$1.1M – 217
2020
Q3
$1.1M Sell
43,256
-12,978
-23% -$818K 0.04% 170
2020
Q2
$4.1M Buy
56,234
+7,901
+16% +$546K 0.16% 121
2020
Q1
$2.54M Buy
48,333
+16,443
+52% +$1.1M 0.18% 111
2019
Q4
$2.61M Buy
+31,890
New +$2.25M 0.11% 100

Other funds holding ABEO

Woodline Partners's ABEO Position: Q3 2026 in Review

Woodline Partners opened a new position in Abeona Therapeutics (ABEO) in Q3 2026: 551,837 shares worth $2.9M. The stake represents 0.01% of the portfolio and ranks #821 among its holdings. This is a return to the name: Woodline Partners previously reported a position in ABEO as recently as Q3 2020.

Woodline Partners first reported a position in ABEO in Q4 2019 and has held it in 5 quarters since. The position peaked at $4.1M in Q2 2020. 115 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.

  • Woodline Partners held 551,837 shares of Abeona Therapeutics worth $2.9M as of Q3 2026.
  • Abeona Therapeutics was a new Woodline Partners position in Q3 2026.
  • Abeona Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #821 holding.
  • Woodline Partners first reported a position in Abeona Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • Woodline Partners's Abeona Therapeutics position peaked at $4.1M in Q2 2020.
  • 115 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.